Evidence map›Paper›PMID 41750508›Full record

ArticleAntibiotics (Basel, Switzerland)2026

The Antimicrobial Peptide C14R Is Active Against All Pathogenic Species of the ESKAPE Group.

Daniel Gruber, Verena Vogel, Jan-Christoph Walter, Grigory Bolotnikov, Armando Rodríguez, Nico Preising, Ludger Ständker, Carolina Firacative, Barbara Spellerberg, Ann-Kathrin Kissmann and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Comparative Genomic and Functional Characterization ofInternational journal of molecular sciences · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Daniel GruberInstitute of Pharmaceutical Biotechnology, Ulm University, 89081 Ulm, Germany.ORCID 0009-0007-7142-1039
Verena VogelInstitute of Medical Microbiology and Hygiene, University Clinic of Ulm, Frauensteige 12, 89075 Ulm, Germany.
Jan-Christoph WalterInstitute of Pharmaceutical Biotechnology, Ulm University, 89081 Ulm, Germany.
Grigory BolotnikovInstitute of Pharmaceutical Biotechnology, Ulm University, 89081 Ulm, Germany.
Armando RodríguezULMTeC Core Facility for Functional Peptidomics, Faculty of Medicine, Ulm University, 89081 Ulm, Germany.ORCID 0000-0001-5921-3770
Nico PreisingULMTeC Core Facility for Functional Peptidomics, Faculty of Medicine, Ulm University, 89081 Ulm, Germany.
Ludger StändkerULMTeC Core Facility for Functional Peptidomics, Faculty of Medicine, Ulm University, 89081 Ulm, Germany.ORCID 0000-0002-8436-4260
Carolina FiracativeStudies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, School of Medicine and Health Sciences, Universidad de Rosario, Bogota 111221, Colombia.ORCID 0000-0001-7547-5172
Barbara SpellerbergInstitute of Medical Microbiology and Hygiene, University Clinic of Ulm, Frauensteige 12, 89075 Ulm, Germany.ORCID 0000-0001-7552-8764
Ann-Kathrin KissmannInstitute of Pharmaceutical Biotechnology, Ulm University, 89081 Ulm, Germany.ORCID 0000-0002-7164-0166
Frank RosenauInstitute of Pharmaceutical Biotechnology, Ulm University, 89081 Ulm, Germany.ORCID 0000-0002-9297-6419

Funding

Anschubfinanzierung A 2025 of Ulm University A 2025Austrian Research Promotion Agency 915477Deutsche Forschungsgemeinschaft 465229237Förderstelle Wirtschaft, Tourismus und Technologie (WST) WST-F-5035462/004-2024Gesellschaft für Forschungsförderung (GFF) of Lower Austria FTI22-G-012
6 · The paper itself

Abstract

The global rise in antimicrobial resistance among the ESKAPE pathogens represents a major challenge to public health. Here, we report the broad-spectrum antibacterial activity of the synthetic antimicrobial and pore-forming peptide C14R against all six ESKAPE species. Using a radial diffusion assay and resazurin-based viability testing, C14R exhibited a potent bactericidal effect with minimum inhibitory concentrations (MICs), defined as the lowest concentration of an antimicrobial agent that completely inhibits visible growth of planktonic microorganisms, ranging from 3.4 µg/mL (

Indexed as

antimicrobial activityC14R peptideESKAPE pathogens

Identifiers

PMID41750508
PMCPMC12938280

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.